Brain Power: Meet José Luis Molinuevo

Through our Brain Power series, we introduce some of the passionate people fueling neuroscience innovation at Lundbeck. Meet José Luis Molinuevo, Head of Experimental Medicine, and one of the world's top-cited researchers.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

09 November, 2022 Corporate Release
Lundbeck’s sales increased by 11% (+6% in local currencies) to DKK 13.6 billion in the first nine months of 2022
08 November, 2022 Corporate Release
Lundbeck raises financial guidance range for the full year 2022
18 October, 2022 Press Release
New study presented at ECNP 2022 finds that vortioxetine improves depressive symptoms and cognitive function in patients with Major Depressive Disorder and co-morbid dementia

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

We need every brain in the game

Out of the Silence: Speaking Up About Migraine